A Study to Evaluate the Safety Tolerability and Immunogenicity of a Modified RNA (mRNA) Vaccine Against Influenza

Brief description of study

This is a Phase 3 randomized, blinded study to assess the safety, tolerability, and efficacy of a single dose of a study mRNA vaccine against flu in healthy individuals. Using an mRNA platform for the flu shot can quicken the manufacturing of the vaccine, which increases the likelihood that the vaccine matches the seasonal strains. You will be asked to complete up to 5 in-person clinic visits in Manhattan over a 6-month period.

Clinical Study Identifier: s22-00762
ClinicalTrials.gov Identifier: NCT05540522
Principal Investigator: Lalitha Parameswaran.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.